ArticleJournal of Cancer2014
Transcatheter arterial chemoembolization for intermediate-stage hepatocellular carcinoma: clinical outcome and safety in elderly patients.
Article in Journal of Cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Hepatocellular carcinoma in the elderly: Meta-analysis and systematic literature review.World journal of gastroenterology · 2015Pooled it
- Safety and efficacy of TACE combined with immune checkpoint inhibitors plus molecular targeted therapies in older adults with unresectable hepatocellular carcinoma.Journal of cancer research and clinical oncology · 2025Article
- The impact of age on the survival outcomes of hepatocellular carcinoma patients after transarterial chemoembolization: A systematic review and meta-analysis.Pakistan journal of medical sciences · 2025Review
- Outcome and Prognosis of Invasive Treatment for Hepatocellular Carcinoma in Very Elderly Patients Over 90 Years Old.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2025Article
- Age and clinical spectrum of COVID-19 are associated with safety of transarterial chemoembolization in hepatocellular carcinoma: a retrospective cohort study.Journal of gastrointestinal oncology · 2024Article
- The efficacy of treatment for hepatocellular carcinoma in elderly patients.Journal of liver cancer · 2023Article
- Safety and Effectiveness of Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Aged Greater versus Less Than 80 Years.Clinical interventions in aging · 2023Article
- Retrograde venous coil embolization prior to transarterial chemoembolization in hepatocellular carcinoma with arterio-hepatic venous shunts.Diagnostic and interventional radiology (Ankara, Turkey) · 2022Article
- Aging of Liver in Its Different Diseases.International journal of molecular sciences · 2022Review
- Inflammatory Indexes as Prognostic Factors of Survival in Geriatric Patients with Hepatocellular Carcinoma: A Case Control Study of Eight Slovak Centers.Journal of clinical medicine · 2022Article
- Safety and Efficacy of Transarterial Chemoembolization in Elderly Patients with Intermediate Hepatocellular Carcinoma.Cancers · 2022Article
- Article
- Is the treatment outcome of hepatocellular carcinoma inferior in elderly patients?World journal of gastroenterology · 2019Review
- Transcatheter arterial chemoembolization (TACE) versus hepatectomy in hepatocellular carcinoma with macrovascular invasion: a meta-analysis of 1683 patients.Journal of Cancer · 2017Article
- Hepatocellular carcinoma in elderly patients: challenges and solutions.Journal of hepatocellular carcinoma · 2016Review
- Hepatic arterial administration of sorafenib and iodized oil effectively attenuates tumor growth and intrahepatic metastasis in rabbit VX2 hepatocellular carcinoma model.International journal of clinical and experimental pathology · 2014Article
- Characteristics and Outcomes of Extreme Elderly Patients With Hepatocellular Carcinoma in South Korea.In vivo (Athens, Greece)Article
- A Review of Hepatocellular Carcinoma in Elderly Patients Focused on Management and Outcomes.In vivo (Athens, Greece)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimThe aim of our study was to compare clinical outcomes between elderly patients aged ≥75 years (elderly group, n=66) with intermediate hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) and younger patients aged <75 years (control group, n=84) with intermediate HCC undergoing TACE.
methodsClinical outcomes, including overall survival (OS) and tumor response rate at initial therapy, were compared between these two groups.
resultsThe median survival time and the 1- and 3-year cumulative OS rates were 2.90 years and 84.1% and 48.0%, respectively, in the elderly group and 2.44 years and 78.2% and 39.3%, respectively, in the control group (p=0.887). The objective response rate in the elderly group was 81.8% (54/66 patients), while that in the control group was 78.6% (66/84 patients) (p=0.227).
conclusionElderly patients with intermediate HCC undergoing TACE had a prognosis comparable with that of younger patients with intermediate HCC undergoing TACE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.